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Purpose: To determine the effects of mitomycin C (MMC) on the expression of chymase and mast cells in the conjunctival
scar after trabeculectomy.
Methods: Ten eyes of five monkeys were used. Three eyes underwent trabeculectomy with MMC (MMC-treated), four
eyes had trabeculectomy without MMC (placebo-treated), and three eyes served as control eyes. Intraocular pressure was
measured before and three weeks after surgery. The scores of the degree of conjunctival adhesion were evaluated.
Immunohistochemistry was used to analyze the densities of proliferative cell nuclear antigen-positive cells, chymase-
positive cells, and mast cells. The ratio of collagen fiber areas to conjunctival and scleral lesions was analyzed by Mallory-
Azan staining.
Results: After trabeculectomy, the intraocular pressure reduction of MMC-treated eyes was significantly different from
placebo-treated and control eyes (p=0.032, 0.035). The adhesion score of MMC-treated eyes was also significantly lower
than that of placebo-treated eyes (p=0.034). Densities of proliferative cell nuclear antigen-positive cells, chymase-positive
cells, and areas of collagen fiber in conjunctival and scleral lesions were significantly decreased in MMC-treated eyes,
compared with placebo-treated eyes (p=0.034, 0.034, 0.049, respectively). There was a tendency for the density of mast
cells to be suppressed in MMC-treated eyes (p=0.157).
Conclusions: Chymase might be involved in one of the mechanisms by which MMC suppresses scar formation after
trabeculectomy.
In  trabeculectomy,  mitomycin  C  (MMC)  maintained
good blebs and greatly improved the results of glaucoma
surgery [1-3]. However, by making thin blebs with MMC,
there is an increased risk of complications such as infectious
endophthalmitis [4-6]. As a mechanism of MMC action, it is
commonly  accepted  that  inhibiting  fibroblast  proliferation
leads to decreased conjunctival adhesion and maintaining the
bleb [7].
When tissues are damaged by surgery in vivo, blood cells
are  released  from  blood  vessels,  and  macrophages  from
monocytes  appear  in  about  12  h,  reaching  peak  numbers
around day three. These macrophages activate inflammatory
cells, including fibroblasts and lymphocytes. T-cells appear
on the fifth day, and after reaching a peak in numbers by the
end of two weeks, they are activated into specific T-cells,
which release various cytokines to control the activity and
proliferation of fibroblasts. Thus, fibroblasts appear and are
activated  at  least  12  h  after  surgery  by  macrophages  and
various cytokines that are released from T-cells [8-10]. In
terms of the pharmacokinetics of MMC, the t1/2 in blood
doses of 30, 20, and 10 (mg/body) is 50.2, 42.8, and 10.0
Correspondence to: Tetsuya Sugiyama, M.D., Ph.D., Department of
Ophthalmology,  Osaka  Medical  College,  2-7  Daigaku-machi,
Takatsuki City, Osaka 569-8686, Japan; Phone: +81-72-683-1221,
FAX: +81-72-681-8195: e-mail: tsugiyama@poh.osaka-med.ac.jp
minutes, respectively, following intravenous administration
[11]. This suggests that the half-life of MMC is short. Because
we use MMC at a dosage of less than 1% on the sclera for
several minutes in trabeculectomy, its effective lifespan seems
to be less than several hours. Therefore, it seems unreasonable
that  MMC  directly  suppresses  fibroblast  adhesion  in  the
conjunctive blebs, since fibroblasts do not appear for at least
12 h after surgery. Other mechanisms must therefore exist
whereby MMC suppresses proliferation of fibroblasts.
It is known that mast cells increase in number in the lesion
where  inflammation  occurs  after  surgery  [12].  Mast  cells
release  various  kinds  of  inflammatory  mediators  such  as
histamine, serotonin, cytokines, and serine proteases, which
play  important  roles  during  adhesion  formation  [13].
Chymase is a chymotrypsin-like serine protease contained in
the secretory granules of mast cells. Human mast cells are
classified into two groups: tryptase- and chymase-positive
mast cells, and tryptase-positive and chymase-negative mast
cells.  Most  mast  cells  are  of  the  former  group  in  normal
conjunctiva, though the latter increases in allergic diseases
[14]. Previous reports demonstrated that chymase induces the
accumulation  of  neutrophils,  eosinophils,  and  other
inflammatory cells, and promotes fibril formation of type 1
procollagen  into  collagen  fibers  [15,16].  We  previously
reported  that  chymase  stimulated  the  proliferation  of
fibroblasts  derived  from  canine  Tenon’s  capsule,  while  a
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2029chymase  inhibitor  suppressed  the  proliferation  of  the
fibroblasts [17]. In this study, we tested the hypothesis that
chymase  might  be  involved  in  the  mechanism  of  bleb
maintenance by MMC, using monkey eyes.
METHODS
Animals: Five monkeys (Macaca fascicularis) weighing 5.1
kg–10.0 kg were purchased from Keari Co. (Osaka, Japan).
Monkeys  were  housed  in  an  air-conditioned  room  at
approximately 23 °C and 60% humidity with a 12h:12h light-
dark  cycle.  Experimental  procedures  for  animals  were
conducted in accordance with the ARVO Statement for Use
of Animals in Ophthalmic and Vision Research.
Surgical  technique:  Monkeys  were  anesthetized  with
ketamine  hydrochloride  (10  mg/kg  subcutaneously)
(Daiichisankyo Prophama Co., Tokyo, Japan) and maintained
with  pentobarbital  (35  mg/kg  intravenously;  Dainippon
Sumitomo Pharma Co., Osaka, Japan). In the conjunctival
sclera flap model, a 10 mm fornix-based conjunctival flap and
a 3 mm triangle of single scleral flap were created. A sponge
(M.Q.A.  sponge;  Inami  Co.,  Tokyo,  Japan)  treated  with
MMC, and diluted to 0.04% in distilled water, was placed
between the conjunctiva and sclera for 5 min. The scleral
incision  was  closed  with  10.0  nylon  sutures  and  the
conjunctival incision was closed with 9.0 silk sutures.
Seven  eyes  from  four  monkeys  underwent
trabeculectomy:  MMC  was  applied  to  three  eyes  of  two
monkeys (MMC-treated eyes), and a placebo was applied to
four  eyes  of  three  monkeys  (placebo-treated  eyes).  The
remaining three eyes of two monkeys, which did not undergo
trabeculectomy,  served  as  control  eyes.  The  intraocular
pressure (IOP) of each eye was measured before, and three
weeks after, surgery. The IOP was measured with a calibrated
Figure  1.  Reduction  in  intraocular  pressure  three  weeks  after
trabeculectomy  in  control,  placebo-,  and  mitomycin  C  (MMC)-
treated  eyes.  Values  are  represented  as  means±SE.  The  asterisk
indicates p<0.05 compared with placebo-treated or control eyes.
pneumatonometer  (Model  30  Classic,  Medtronic  Solan,
Jacksonville, FL, USA) under general anesthesia in a face-up
position. Three weeks after surgery, monkeys were sacrificed
by injecting a lethal dose of potassium chloride, and the degree
of adhesion was assessed. The flap (5×10 mm2) was harvested
without  detaching  the  conjunctival  and  scleral  lesions  for
histological analysis.
Adhesion scores: The adhesion degree was determined by
comparing the percent of the area of adhesion to the whole
flap area (5×10 mm2) as an index. Scores were determined as
follows: Score 1, the flap could be detached by lightly lifting
the flap, or the area of adhesion was not more than 20%; Score
2, the area of adhesion was between 20 and 40%; Score 3, the
area of adhesion was between 40% and 60%; Score 4, the area
of adhesion was between 60% and 100%
Histology  and  immunohistochemistry:  Conjunctival  and
scleral  tissue  specimens  were  fixed  with  10%  buffered
formalin and embedded in paraffin. Sections with a thickness
of 5 µm were cut, mounted on silanized slides (Dako Japan,
Kyoto, Japan), and deparaffinized with xylenes and a series
of graded ethanol solutions. Each section was stained with
azan and toluidine blue to identify collagen fibers and mast
cells, respectively.
Immunohistochemical analysis was performed on at least
two paraffin blocks of resected conjunctival and scleral tissue
per monkey. To retrieve the antigen, sections were pretreated
with 10 mM citrate buffer, pH 6.0, and autoclaved for 15 min
at  120  °C,  before  immunohistochemical  staining  with
proliferative  cell  nuclear  antigen  (PCNA)  and  chymase
Figure 2. Scores of adhesion formation assessed three weeks after
trabeculectomy in placebo- and mitomycin C (MMC)-treated eyes.
Values are represented as means±SE. The asterisk indicates p<0.05
compared with placebo-treated eyes.
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2030antibodies.  Sections  were  soaked  in  absolute  methanol
containing  0.3%  hydrogen  peroxide  for  30  min  at  room
temperature to remove endogenous peroxidase activity. To
suppress non-specific binding, sections were incubated with
1.5% non-immune goat serum for 20 min. Sections were then
incubated  with  mouse  monoclonal  antibody  2D11G10D
(Katakura  Industries  Co.,  Saitama,  Japan)  against  human
chymase for 60 min at room temperature. This antibody can
detect human chymase in formalin-fixed, paraffin-embedded
tissue  sections  [18].  After  washing  in  phosphate-buffered
saline (PBS), the slides were subsequently incubated with
biotin-conjugated goat anti-mouse immunoglobulin (Ig) G
antibody for 30 min. After washing with PBS, the sections
were then incubated with avidin-biotin-peroxidase complex
(Dako Japan) for 30 min and washed once more with PBS.
Finally,  sections  were  incubated  with  0.03%  hydrogen
peroxide and 0.05% 3,3-diaminobenzidine. The slides were
then  washed  in  running  tap  water,  counterstained  with
hematoxylin,  and  mounted  in  Canadian  balsam.  Non-
immunized mouse IgG was used as a negative control. No
significant immunohistochemical reactions occurred in the
control sections.
Measurement of fibrotic areas: One slice obtained from each
specimen was Mallory-Azan stained, and the blue area was
defined as the fibrotic area. In each specimen, the ratio of the
fibrotic  area  to  the  total  area  at  40×  magnification  was
Figure 3. Immunohistochemistry for proliferative cell nuclear antigen (PCNA). A: Typical photographs of placebo- (left) and mitomycin C
(MMC)- (right) treated eyes stained with PCNA three weeks after trabeculectomy. Bars represent 100 μm. Arrows demonstrate positive cells.
B: The numbers of proliferative cell nuclear antigen-positive cells per mm2 in control, placebo-, and MMC-treated eyes are shown. Values
are represented as means±SE. The asterisk indicates p<0.05 compared with placebo-treated eyes.
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2031measured using a computerized morphometric system (VHX
Digital Microscope, Keyence Co., Osaka, Japan).
Measurement of PCNA-positive cells, chymase-positive cells,
and mast cells: We counted PCNA-positive cells, chymase-
positive  cells,  and  mast  cells  at  the  sites  where  they
accumulated in the conjunctival and scleral lesions, using a
light  microscope  (number  per  100×  field).  The  average
number of PCNA-positive cells and chymase-positive cells
and mast cells in five selected fields was calculated.
Statistical analysis: IOPs were evaluated by Student’s t-test
for  unpaired  data.  Adhesion  scores,  densities  of  PCNA-
positive cells, chymase-positive cells, mast cells, and collagen
areas  were  evaluated  by  the  Mann-Whitney  U  test.
Differences  were  considered  statistically  significant  at
p<0.05.
RESULTS
IOPs before and after surgery: Before surgery, the IOP (mean
±standard error of the mean (SE), mmHg) was 19.0±2.0 in the
Figure 4. Immunohistochemistry for chymase. A: Typical photographs of placebo- (left) and mitomycin C (MMC)- (right) treated eyes stained
with chymase antibodies three weeks after trabeculectomy. Bars represent 100 μm. Arrows demonstrate positive cells. B: The numbers of
chymase-positive cells per mm2 in control, placebo- and MMC-treated eyes are shown. Values are represented as means±SE. The asterisk
indicates p<0.05 compared with placebo-treated eyes.
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2032control  eyes,  18.5±2.5  in  the  placebo-treated  eyes,  and
19.0±1.0 in the MMC-treated eyes. There was no significant
difference among these groups. IOP reduction after surgery in
MMC-treated eyes was significantly different from placebo-
treated or control eyes (p=0.0317, 0.0353, Figure 1).
The adhesion score: The adhesion score in MMC-treated eyes
was significantly decreased compared with placebo-treated
eyes (p=0.0339, Figure 2).
Histologic study: PCNA -positive cells in MMC-treated eyes
were  significantly  decreased  compared  to  placebo-treated
eyes (p=0.0339, Figure 3). The number of chymase-positive
cells in placebo-treated eyes had a tendency to be greater than
that in control eyes (p=0.1649), while that in MMC-treated
eyes  was  significantly  decreased  compared  with  placebo-
treated eyes (p=0.0339, Figure 4). There was no significant
difference in the number of mast cells among the three groups.
However, the number of mast cells had a tendency to be
greater  in  placebo-treated  eyes  than  in  control  eyes
(p=0.3545), while mast cells had a tendency to be suppressed
in MMC-treated eyes compared with placebo-treated eyes
(p=0.1573, Figure 5). Collagen fiber areas in MMC-treated
eyes were significantly decreased compared with placebo-
treated eyes (p=0.0495, Figure 6).
Figure 5. Detection of mast cells. A: Typical photographs of placebo- (left) and mitomycin C(MMC)- (right) treated eyes stained with toluidine
blue three weeks after trabeculectomy. Bars represent 100 μm. Arrows demonstrate positive cells. B: The numbers of mast cells per mm2 in
control, placebo- and MMC-treated eyes are shown. Values are represented as means±SE. The symbol (†) indicates p<0.2 compared with
placebo-treated eyes.
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2033DISCUSSION
The results of the current study show that chymase-positive
cells in MMC-treated monkey eyes after trabeculectomy were
significantly decreased, compared with placebo-treated eyes.
Mast cells also tended to be suppressed in MMC-treated eyes.
These results suggest that chymase may be involved in at least
one of the mechanisms by which MMC exerts its effects.
In this study, the numbers of chymase-positive cells and
mast cells had a tendency to be increased in placebo-treated
eyes, compared with control eyes, though the differences were
not significant. These findings suggest that chymase and mast
cells are induced by glaucoma surgery. These results agree
with our previous report using canine eyes, even though the
animal species were different [17]. In MMC-treated eyes, the
adhesion  score  was  suppressed;  and  PCNA-positive  cells,
which  show  changes  from  non-proliferating  cells  to
proliferating  cells,  were  significantly  decreased,  in
comparison with placebo-treated eyes. These findings suggest
that  MMC  works  against  proliferation  and  adhesion  after
glaucoma  filtration  surgery,  as  some  other  studies  have
reported  [1-3,7,19,20].  Compared  to  placebo-treated  eyes,
collagen fiber areas of MMC-treated eyes were significantly
decreased, whereas other reports have suggested that collagen
increases after glaucoma surgery [21,22]. In comparison to
Figure 6. Detection of collagen fibers. A: Typical photographs of placebo- (left) and mitomycin C(MMC)- (right) treated eyes stained with
azan three weeks after trabeculectomy. Bars represent 500 μm. Arrows demonstrate collagen fibers. B: The ratios of collagen fiber areas to
conjunctival and scleral lesions in control, placebo and MMC-treated eyes are shown. Values are represented as means±SE. The asterisk
indicates p<0.05 compared with placebo-treated eyes.
Molecular Vision 2009; 15:2029-2036 <http://www.molvis.org/molvis/v15/a217> © 2009 Molecular Vision
2034placebo-treated eyes, chymase-positive cells of MMC-treated
eyes were significantly decreased. Nevertheless, there are no
reports that MMC is directly related to chymase. Mast cells in
MMC-treated eyes had a tendency to be suppressed, compared
with placebo-treated eyes, although there are no reports that
show  a  relationship  between  MMC  and  mast  cells.  Since
chymase exists in the secretory granules that mast cells release
[15], it is not inconsistent that mast cells are also decreased as
chymase decreases. Nevertheless, the results showing that
chymase-positive cells were significantly inhibited, although
the suppression of mast cells was not significant, suggest that
MMC might have a relatively selective effect on chymase.
It was previously reported that chymase was involved in
the  adhesion  formation  of  tissues,  in  terms  of  fibroblast
proliferation  [23].  In  cultured  human  fibroblasts,  the
concentration of transforming growth factor-β (TGF-β) in the
medium  was  significantly  increased  after  the  injection  of
human chymase. Therefore, human chymase increased the
cell proliferation of human fibroblasts through activation of
the  latent  TGF-β.  The  same  report  also  suggested  that
chymase induced the expression of collagen I and collagen III
genes in cardiac tissues, which leads to fibrosis. In a hamster
experimental model of peritoneal adhesion, the scores for
adhesion formation, chymase activity, and TGF-β levels after
surgery were significantly increased in the placebo-treated
group, while they were significantly suppressed by treatment
with chymase inhibitor [24]. Furthermore, in a hamster model
of glaucoma filtration surgery, chymase activity tended to be
higher than in control eyes, and mast cells were increased in
the  subconjunctival  tissue  and  around  the  tunnel  opening
[25].
We  also  reported  that  chymase  promoted  cell
proliferation  of  fibroblasts  using  canine  Tenon’s  capsule,
while chymase inhibitor suppressed proliferation [17]. Other
in vitro studies put forward the concept of targeting TGF-β
signaling,  which  is  induced  by  chymase,  to  prevent  scar
formation after filtering glaucoma surgery. Activation of the
PI3K-Akt  pathway  by  TGF-β2  may  be  essential  for  the
expression  and  activity  of  tissue  transglutaminase  in
subconjunctival  fibroblasts.  This  pathway  may  play  an
important  role  in  the  pathogenesis  of  wound  healing  and
fibrogenic reactions in subconjunctival tissue [26]. Another
study reported the association of filtering bleb scarring with
an  abundant  expression  of  TGF-β  receptors  in  activated
fibroblasts  and  the  deposition  of  the  fibrogenic  ED-A
fibronectin splice-variant [27].
Chymase is immediately released from mast cell granules
upon tissue damage, such as from surgery, and binds to the
extracellular matrix, where it continues to function for several
weeks [28,29]. However, MMC probably does not affect the
proliferation of fibroblasts appearing around 12 h after tissue
damage, because the half-life of MMC is less than 1 h. It is
more likely that MMC initially suppresses the proliferation of
mast cells, including chymase-positive cells. As a result of
this, fibroblast proliferation is then restrained. In fact, topical
instillation of an anti-mast-cell agent, tranilast, was useful for
filtering bleb formation and IOP reduction [30]. Therefore,
suppression of mast cells might be related to formation of the
filtering bleb. In addition, chymase inhibition might play a
role in maintaining filtering blebs for an extended period of
time. It has been reported that a chymase inhibitor prevents
adhesion for up to three months in an abdomen adhesion
model [31], so bleb formation may be maintained for a long
time if MMC inhibits chymase function after tissue injury.
In conclusion, the current study suggests that chymase
might be involved in one of the mechanisms by which MMC
suppresses scar formation after trabeculectomy. Therefore,
inhibition  of  chymase  might  be  useful  for  reducing
conjunctival  adhesion  and  maintaining  bleb  formation.
Further  investigation  is  needed  to  verify  that  chymase
inhibitors are appropriate for glaucoma surgeries.
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